DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Fluoxetine vs. Brief Psychotherapy for Major Depression

Information source: University of Turku
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Major Depressive Disorder

Intervention: Fluoxetine (Drug); Short-term psychodynamic psychotherapy (Behavioral)

Phase: N/A

Status: Completed

Sponsored by: University of Turku

Official(s) and/or principal investigator(s):
Hasse Karlsson, MA, MD, PhD, Principal Investigator, Affiliation: Helsinki University

Summary

In this study we compare two treatments for major depression - fluoxetine and brief

psychodynamic psychotherapy. In addition to more traditional outcome measures, we also measure the densities of 5HT-1A and D-2 receptors before and after the treatment. The main hypothesis is that brief psychotherapy is as effective as fluoxetine.

Clinical Details

Official title: Fluoxetine vs. Brief Psychotherapy in the Treatment of Major Depression - a Randomized Comparative Study

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: HAM-D

Detailed description:

This study is a randomized comparison of two treatments for major depression - fluoxetine

and brief psychodynamic psychotherapy. The patients are recruited from occupational health services and suffer from mild to moderate major depressive disorder. The treatments last for 16 weeks. The main outcome measures include HAM-D, BDI, SOFAS, Rand-36. In addition to more traditional outcome measures, we also measure the densities of 5HT-1A and D-2 receptors before and after the treatment using Positron Emission Tomography (PET) . The main hypothesis is that brief psychotherapy is as effective as fluoxetine, but differences between the treatments are seen in PET scanning.

Eligibility

Minimum age: 20 Years. Maximum age: 60 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- MDD (mild to moderate)

- HDRS 15 or more, age 20-60 years

- No treatment for preceding 4 months

- No DSM-IV axis I or II comorbidity

- No severe somatic illness

- No contraindications for fluoxetine treatment

Locations and Contacts

Additional Information

Starting date: January 2000
Last updated: July 7, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017